Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Myriad Genetics Inc (MYGN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 1,117,230
  • Shares Outstanding, K 68,780
  • Annual Sales, $ 753,800 K
  • Annual Income, $ 125,300 K
  • 36-Month Beta 0.34
  • Price/Sales 1.48
  • Price/Book 1.53

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.41 +1.56%
on 01/18/17
18.81 -16.80%
on 12/19/16
-3.15 (-16.76%)
since 12/16/16
3-Month
15.41 +1.56%
on 01/18/17
20.00 -21.75%
on 10/19/16
-4.26 (-21.40%)
since 10/18/16
52-Week
15.41 +1.56%
on 01/18/17
41.75 -62.51%
on 01/22/16
-24.52 (-61.04%)
since 01/15/16

Most Recent Stories

More News
Myriad Genetics: Evidence Street Reviews EndoPredict Test

Myriad Genetics, Inc. (MYGN) recently announced that Blue Cross Blue Shield Association's technical assessment provider Evidence Street has reviewed its EndoPredict assay.

The EndoPredict(R) Test Receives Positive Coverage Decisions from Multiple Blue Cross Blue Shield Affiliate Plans

Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that multiple Blue Cross Blue Shield (BCBS) affiliate plans have issued positive coverage determinations for...

Myriad Genetics' Unit Releases Favorable Data on Vectra DA

Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience released favorable data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA).

Positive Clinical Utility Results of Crescendo's Vectra(R) DA Test for Rheumatoid Arthritis Published in the Journal Arthritis & Rheumatology

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra DA test to predict treatment response in patients with rheumatoid...

Myriad Genetics: United Rheumatology Selects Vectra DA Test

Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience's Vectra DA assay has been added by United Rheumatology to its clinical practice guidelines for adults with rheumatoid arthritis.

United Rheumatology Issues Clinical Practice Guidelines and Recommends the Vectra(R) DA Test for Adults with Rheumatoid Arthritis

Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that United Rheumatology, a leading professional organization for rheumatologists in the United States...

Will Endopredict Win Myriad's (MYGN) Genomic Testing War?

Myriad Genetics (MYGN) released favorable study results demonstrating the superiority of EndoPredict test over Oncotype Dx on long-term recurrence of breast cancer.

The EndoPredict(R) Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-Positive Breast Cancer Recurrence

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results of a large head-to-head study comparing the efficacy of six tests used to predict...

Myriad Genetics Will Present Results from Six Breast Cancer Studies at SABCS

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that the Company will present six breast cancer studies at the 2016 San Antonio Breast...

Learn how to target a 20% return on Sears Holdings, or get option-trade ideas on Intrexon, Agios Pharmaceuticals, Mattel Inc. and Myriad Genetics or any stock you choose

InvestorsObserver issues critical PriceWatch Alerts for AGIO, MAT, MYGN, SHLD, and XON.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease....

See More

Support & Resistance

2nd Resistance Point 16.68
1st Resistance Point 16.24
Last Price 15.69
1st Support Level 15.48
2nd Support Level 15.16

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.